Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Irene M Ghobrial,Jonathan L Kaufman,David S Siegel,Ravi Vij,Ashraf Badros,Linda Neuman,Hansen Wong,Janet Anderl,Michael Savona

doi:10.1182/blood.v122.21.3184.3184

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Irene M Ghobrial, Jonathan L Kaufman + Show 7 more

https://doi.org/10.1182/blood.v122.21.3184.3184

Copy DOI

Journal: Blood	Publication Date: Nov 15, 2013
Citations: 15

Affiliation: Dana-Farber Cancer Institute, Emory University, Hackensack University Medical Center, Washington University in St. Louis, University of Maryland, Baltimore, Sarah Cannon

#Antitumor Activity In Pts #Waldenström's Macroglobulinemia + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.